Salong Debbarma, Author at Pharmaceutical Business review

Salong Debbarma, Author at Pharmaceutical Business review - Page 37 of 37

Pharmaceutical Business review is using cookies

Salong Debbarma

All articles by Salong Debbarma

Alvotech and Advanz announce MHRA marketing authorisations for Gobivaz

The authorisations are granted for Gobivaz in 50 mg/0.5 mL and 100 mg/mL formulations, available in pre-filled syringes and autoinjectors. The medication is indicated for the treatment of

Leukogene Therapeutics gains FDA ODD status for M2T-CD33

The designation highlights the considerable unmet medical needs of patients with AML and recognises LTI-214’s therapeutic potential as a new treatment for this aggressive form of blood cancer.

Drug Discovery

Research & Development

WellSpan and Johns Hopkins renew partnership for advanced cancer care access

SandboxAQ introduces AQPotency for virtual drug screening

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Gerresheimer at CPHI Frankfurt 2025

Gerresheimer

Suppliers

No data found

Salong Debbarma

All articles by Salong Debbarma

Alvotech and Advanz announce MHRA marketing authorisations for Gobivaz

Leukogene Therapeutics gains FDA ODD status for M2T-CD33